These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

473 related articles for article (PubMed ID: 22939034)

  • 41. Effects of DPP-4 Inhibitor Linagliptin Versus Sulfonylurea Glimepiride as Add-on to Metformin on Renal Physiology in Overweight Patients With Type 2 Diabetes (RENALIS): A Randomized, Double-Blind Trial.
    Muskiet MHA; Tonneijck L; Smits MM; Kramer MHH; Ouwens DM; Hartmann B; Holst JJ; Touw DJ; Danser AHJ; Joles JA; van Raalte DH
    Diabetes Care; 2020 Nov; 43(11):2889-2893. PubMed ID: 32900785
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Efficacy and safety of DBPR108 monotherapy in patients with type 2 diabetes: a 12-week, randomized, double-blind, placebo-controlled, phase II clinical trial.
    Wang W; Yao J; Guo X; Guo Y; Yan C; Liu K; Zhang Y; Wang X; Li H; Wen Z; Wang X; Li S; Xiao X; Liu W; Li Z; Zhang L; Shao S; Ye S; Qin G; Li Y; Li F; Zhang X; Li X; Peng Y; Deng H; Xu X; Zhou L; Huang Y; Cao M; Xia X; Shi M; Dou J; Yuan J
    Curr Med Res Opin; 2020 Jul; 36(7):1107-1115. PubMed ID: 32338063
    [No Abstract]   [Full Text] [Related]  

  • 43. Effects of Dipeptidyl Peptidase-4 Inhibitor Linagliptin on Left Ventricular Dysfunction in Patients with Type 2 Diabetes and Concentric Left Ventricular Geometry (the DYDA 2™ Trial). Rationale, Design, and Baseline Characteristics of the Study Population.
    Giorda CB; Cioffi G; Lucci D; Nada E; Ognibeni F; Mancusi C; Latini R; Maggioni AP;
    Cardiovasc Drugs Ther; 2019 Oct; 33(5):547-555. PubMed ID: 31418140
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Metabolic effects of two years of exenatide treatment on diabetes, obesity, and hepatic biomarkers in patients with type 2 diabetes: an interim analysis of data from the open-label, uncontrolled extension of three double-blind, placebo-controlled trials.
    Buse JB; Klonoff DC; Nielsen LL; Guan X; Bowlus CL; Holcombe JH; Maggs DG; Wintle ME
    Clin Ther; 2007 Jan; 29(1):139-53. PubMed ID: 17379054
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Metabolic effects of pioglitazone in combination with insulin in patients with type 2 diabetes mellitus whose disease is not adequately controlled with insulin therapy: results of a six-month, randomized, double-blind, prospective, multicenter, parallel-group study.
    Mattoo V; Eckland D; Widel M; Duran S; Fajardo C; Strand J; Knight D; Grossman L; Oakley D; Tan M;
    Clin Ther; 2005 May; 27(5):554-67. PubMed ID: 15978304
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Efficacy and safety of linagliptin as add-on therapy to insulin in Chinese patients with type 2 diabetes mellitus: A randomized, double-blind, placebo-controlled trial.
    Yang W; Xu X; Lei T; Ma J; Li L; Shen J; Ye B; Zhu S; Meinicke T
    Diabetes Obes Metab; 2021 Feb; 23(2):642-647. PubMed ID: 33074590
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Rationale, design, and baseline characteristics of the CArdiovascular safety and Renal Microvascular outcomE study with LINAgliptin (CARMELINA
    Rosenstock J; Perkovic V; Alexander JH; Cooper ME; Marx N; Pencina MJ; Toto RD; Wanner C; Zinman B; Baanstra D; Pfarr E; Mattheus M; Broedl UC; Woerle HJ; George JT; von Eynatten M; McGuire DK;
    Cardiovasc Diabetol; 2018 Mar; 17(1):39. PubMed ID: 29540217
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Efficacy and tolerability of acarbose in Asian patients with type 2 diabetes inadequately controlled with diet and sulfonylureas.
    Lin BJ; Wu HP; Huang HS; Juang JH; Sison A; bin Abdul Kadir DK; Cho CG; Sridama W;
    J Diabetes Complications; 2003; 17(4):179-85. PubMed ID: 12810240
    [TBL] [Abstract][Full Text] [Related]  

  • 49. A post-hoc analysis of the comparative efficacy of canagliflozin and glimepiride in the attainment of type 2 diabetes-related quality measures.
    Patel CA; Bailey RA; Vijapurkar U; Meininger G; Blonde L
    BMC Health Serv Res; 2016 Aug; 16(a):356. PubMed ID: 27495291
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Real-world comparison of mono and dual combination therapies of metformin, sulfonylurea, and dipeptidyl peptidase-4 inhibitors using a common data model: A retrospective observational study.
    Lee KA; Jin HY; Kim YJ; Kim SS; Cho EH; Park TS
    Medicine (Baltimore); 2022 Feb; 101(8):e28823. PubMed ID: 35212277
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Fotagliptin monotherapy with alogliptin as an active comparator in patients with uncontrolled type 2 diabetes mellitus: a randomized, multicenter, double-blind, placebo-controlled, phase 3 trial.
    Xu M; Sun K; Xu W; Wang C; Yan D; Li S; Cong L; Pi Y; Song W; Sun Q; Xiao R; Peng W; Wang J; Peng H; Zhang Y; Duan P; Zhang M; Liu J; Huang Q; Li X; Bao Y; Zeng T; Wang K; Qin L; Wu C; Deng C; Huang C; Yan S; Zhang W; Li M; Sun L; Wang Y; Li H; Wang G; Pang S; Zheng X; Wang H; Wang F; Su X; Ma Y; Zhang W; Li Z; Xie Z; Xu N; Ni L; Zhang L; Deng X; Pan T; Dong Q; Wu X; Shen X; Zhang X; Zou Q; Jiang C; Xi J; Ma J; Sun J; Yan L
    BMC Med; 2023 Oct; 21(1):388. PubMed ID: 37814306
    [TBL] [Abstract][Full Text] [Related]  

  • 52. The effect of pioglitazone on glycemic and lipid parameters and adverse events in elderly patients with type 2 diabetes mellitus: a post hoc analysis of four randomized trials.
    Rajagopalan R; Xu Y; Abbadessa M;
    Am J Geriatr Pharmacother; 2006 Jun; 4(2):123-33. PubMed ID: 16860259
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Results of the glucose-lowering effect of WelChol study (GLOWS): a randomized, double-blind, placebo-controlled pilot study evaluating the effect of colesevelam hydrochloride on glycemic control in subjects with type 2 diabetes.
    Zieve FJ; Kalin MF; Schwartz SL; Jones MR; Bailey WL
    Clin Ther; 2007 Jan; 29(1):74-83. PubMed ID: 17379048
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Long-Term Efficacy and Safety of Linagliptin in a Japanese Population with Type 2 Diabetes Aged ≥ 60 Years Treated with Basal Insulin: A Randomised Trial.
    Araki E; Unno Y; Tanaka Y; Sakamoto W; Miyamoto Y
    Adv Ther; 2019 Oct; 36(10):2697-2711. PubMed ID: 31482511
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Predictors of response to dipeptidyl peptidase-4 inhibitors: evidence from randomized clinical trials.
    Monami M; Cremasco F; Lamanna C; Marchionni N; Mannucci E
    Diabetes Metab Res Rev; 2011 May; 27(4):362-72. PubMed ID: 21309062
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Yogliptin monotherapy in type 2 diabetes: A 12-week randomized, double-blind, placebo-controlled phase II study.
    Wang X; Wang Y; Yong X; Wu B; Sun Z; Lou N; Wen Q; Zhang Y; Li S; Li J; He Y; Cheng J; Zhong X; Shen J; Yang W
    J Diabetes; 2022 Dec; 14(12):822-830. PubMed ID: 36515221
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Efficacy and safety of adding the dipeptidyl peptidase-4 inhibitor alogliptin to metformin therapy in patients with type 2 diabetes inadequately controlled with metformin monotherapy: a multicentre, randomised, double-blind, placebo-controlled study.
    Nauck MA; Ellis GC; Fleck PR; Wilson CA; Mekki Q;
    Int J Clin Pract; 2009 Jan; 63(1):46-55. PubMed ID: 19125992
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Safety and tolerability of linagliptin in Asians with type 2 diabetes: a pooled analysis of 4457 patients from 21 randomized, double-blind, placebo-controlled clinical trials.
    Kanasaki K; Qu S; Yamamoto F; Schepers C; Sani Simões R; Yabe D; Ji L
    Expert Opin Drug Saf; 2022 Mar; 21(3):425-434. PubMed ID: 34711126
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Dose-ranging efficacy of sitagliptin, a dipeptidyl peptidase-4 inhibitor, in Japanese patients with type 2 diabetes mellitus.
    Iwamoto Y; Taniguchi T; Nonaka K; Okamoto T; Okuyama K; Arjona Ferreira JC; Amatruda J
    Endocr J; 2010; 57(5):383-94. PubMed ID: 20332588
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Pharmacokinetic and pharmacodynamic evaluation of linagliptin in African American patients with type 2 diabetes mellitus.
    Friedrich C; Glund S; Lionetti D; Kissling CJ; Righetti J; Patel S; Graefe-Mody U; Retlich S; Woerle HJ
    Br J Clin Pharmacol; 2013 Sep; 76(3):445-54. PubMed ID: 23331248
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 24.